PHASE III TRIAL OF CRISNATOL MESYLATE VS BCNU IN BRAIN TUMOR PATIENTS

甲磺酸克瑞那醇 VS BCNU 在脑肿瘤患者中的 III 期试验

• 批准号: 6113809
• 负责人: STEVEN K GUDEMAN
• 金额: $ 1.58万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6113809
• 关键词: antineoplastics; carmustine; clinical research; drug screening /evaluation; glioblastoma multiforme; human mortality; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; neoplasm /cancer relapse /recurrence; neoplastic process

The primary objective is to determine whether Crisnatol Mesylate is superior to BCNU as measured by time to tumor recurrence or progression in patients with glioblastoma multiforme. A secondary objective is to determine whether Crisnatol is superior to BCNU as measured by overall survival in patients with glioblastoma multiforme.

主要目的是确定甲磺酸克里那托是否 根据至肿瘤复发或进展的时间测量，上级于BCNU 在多形性胶质母细胞瘤患者中。 第二个目标是 确定Crisnatol是否上级于BCNU，通过总体测量 多形性胶质母细胞瘤患者的生存率。